1 To evaluate the efficacy of two doses of MK-7655 imipenemcilastatin 250 mg and 125 mg as compared with imipenemcilastatin alone with respect to the clinical response assessment profile in the treatment of adult patients with cIAI at completion of IV study therapy DCIV 2 To evaluate the safety and tolerability profile of two doses of MK- 7655 imipenemcilastatin 250 mg and 125 mg
Data and Resources
- A Phase II Randomized Active Comparator-Controlled Clinical Trial to Study the Safety Tolerability and Efficacy of MK-7655 ImipenemCilastatin Versus ImipenemCilastatin Alone in Patients with Complicated Intra-Abdominal Infection cIAIjson
1 To evaluate the efficacy of two doses of MK-7655 imipenemcilastatin 250 mg...
|Release Date|| |
|Public Access Level|| |